Special Import - Mounjaro Kwikpen 5mg 1pen- 2.4ml solution - 4doses

Mounjaro Kwikpen 5mg 1pen- 2.4ml solution - 4doses

Description:

Mounjaro Kwikpen 5mg 2.4ml solution (4 doses) is a prescription injectable medicine used for the management of type 2 diabetes and for chronic weight management in adults, as an adjunct to diet and exercise. It contains tirzepatide, a dual GIP and GLP-1 receptor agonist that helps improve blood sugar control and supports significant weight loss. This pre-filled, ready-to-use subcutaneous injection pen is designed for once-weekly dosing and convenient self-administration under medical supervision.

Indications:

• Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• – As monotherapy when metformin is inappropriate due to intolerance or contraindications.
• – In combination with other antidiabetic medicines (e.g. metformin, SGLT2 inhibitors, insulin) when additional glycemic control is needed.
• Improvement of glycemic control by lowering fasting and postprandial blood glucose levels and HbA1c in adults with type 2 diabetes.
• Weight management (weight loss and weight maintenance) in adults as an adjunct to a reduced-calorie diet and increased physical activity in:
• – Obesity: initial BMI ≥ 30 kg/m2.
• – Overweight: initial BMI ≥ 27 kg/m2 to < 30 kg/m2 in the presence of at least one weight-related comorbid condition (e.g. hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
• May help reduce cardiometabolic risk factors associated with excess weight and type 2 diabetes (such as elevated blood glucose, high blood pressure, and abnormal lipids) when used as part of a comprehensive management plan.

Active Ingredients / Key Components:

• Active ingredient: Tirzepatide – 5 mg per dose.
• Concentration: The reference product is Mounjaro 5 mg/0.5 ml; each dose delivers 5 mg tirzepatide in 0.5 ml solution for injection.
• Pen content: 1 pre-filled Kwikpen containing a total of 2.4 ml solution, providing 4 once-weekly doses.
• Pharmaceutical form: Clear, colorless to slightly yellow solution for subcutaneous injection.
• Excipients: Detailed excipient list (e.g. buffers, stabilizers, preservatives) is not available in the provided data. Please refer to the official package leaflet for the full list of ingredients.

Dosage & Administration / How to Use:

• General dosing:
• – Starting dose: 2.5 mg tirzepatide once weekly for 4 weeks (usually with a lower-strength pen, as prescribed by your doctor).
• – After 4 weeks, the dose is increased to 5 mg once weekly. This Kwikpen 5 mg is typically used at this stage and for maintenance, according to your doctor’s plan.
• – If additional glycemic or weight control is needed, the dose may be increased in 2.5 mg increments (e.g. 7.5 mg, 10 mg, 12.5 mg, 15 mg) after at least 4 weeks on the current dose, as directed by your physician.
• – Recommended maintenance doses: 5 mg, 10 mg, or 15 mg once weekly.
• – Maximum dose: 15 mg once weekly.
• Route of administration:
• – For subcutaneous injection only (under the skin).
• – Recommended injection sites: abdomen, thigh, or upper arm.
• – Rotate injection sites with each dose to reduce the risk of irritation or lipodystrophy.
• Timing of administration:
• – Inject once weekly, on the same day each week, at any time of the day.
• – Can be administered with or without food.
• Use with insulin and other antidiabetics:
• – If used together with insulin, inject Mounjaro and insulin at separate injection sites; do not mix in the same syringe.
• – Your doctor may adjust the dose of insulin or other antidiabetic medications to reduce the risk of hypoglycemia.
• Administration steps (general guidance):
• 1. Wash hands and prepare a clean area.
• 2. Check the pen label to confirm the correct strength (5 mg) and inspect the solution; do not use if cloudy, discolored, or contains particles.
• 3. Attach a new sterile needle according to the pen instructions.
• 4. Prime the pen if required by the manufacturer’s instructions (refer to the official user guide).
• 5. Set the prescribed dose (5 mg) on the dose selector.
• 6. Choose an injection site (abdomen, thigh, or upper arm), clean with an alcohol swab, and let it dry.
• 7. Insert the needle into the skin and press the injection button fully; hold for the recommended time to ensure full dose delivery.
• 8. Remove the needle, apply gentle pressure with a cotton pad if needed, and safely dispose of the needle in a sharps container.
• 9. Store the pen as recommended between uses.
• Missed dose:
• – If you miss a dose, administer it as soon as possible within 4 days (96 hours) after the missed dose.
• – If more than 4 days have passed, skip the missed dose and take the next dose on the regularly scheduled day.
• – Do not take two doses within 3 days (72 hours) of each other.
• Always follow your doctor’s instructions and the official patient information leaflet. Do not change your dose without medical advice.

Clinical Benefits:

• Helps significantly lower blood glucose levels and HbA1c in adults with type 2 diabetes when used with diet and exercise.
• Supports clinically meaningful weight loss and long-term weight management in adults with obesity or overweight with weight-related comorbidities.
• Improves both fasting and post-meal (postprandial) glucose control through dual GIP and GLP-1 receptor agonism.
• May reduce insulin requirements when used in combination with insulin or other antidiabetic therapies, under medical supervision.
• Once-weekly dosing with a pre-filled Kwikpen enhances convenience and may improve treatment adherence compared to daily injections.
• Helps address multiple cardiometabolic risk factors associated with type 2 diabetes and obesity as part of a comprehensive lifestyle and medical plan.

Warnings & Contraindications:

• Mounjaro (tirzepatide) is a prescription medicine and must be used only under the supervision of a healthcare professional.
• Contraindicated in patients with known hypersensitivity to tirzepatide or any of the excipients.
• Not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Not a substitute for insulin in insulin-dependent patients.
• Use with caution in patients with a history of pancreatitis; discontinue and seek medical attention if severe abdominal pain occurs.
• Gastrointestinal adverse effects (nausea, vomiting, diarrhea) may occur, especially during dose escalation; dehydration may result from severe GI symptoms.
• May increase the risk of hypoglycemia when used in combination with insulin or insulin secretagogues (e.g. sulfonylureas); dose adjustments of concomitant therapy may be required.
• Limited data in patients with severe renal or hepatic impairment; use with caution and under close monitoring.
• Thyroid-related warnings: GLP-1 receptor agonists have been associated with thyroid C-cell tumors in rodents. Although the relevance to humans is unknown, patients should report symptoms such as a neck mass, dysphagia, dyspnea, or persistent hoarseness.
• Not recommended in pregnancy unless clearly needed; weight loss medications are generally avoided during pregnancy. Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
• Consult your doctor before use if you are pregnant, nursing, taking other medications, or have medical conditions such as pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney or liver problems, or thyroid disorders.
• Do not share your Mounjaro Kwikpen with anyone else, even if the needle is changed, to avoid transmission of infections.
• Keep out of reach of children.
• This product should be used strictly according to your doctor’s prescription and the official patient information leaflet.

Side Effects:

• Common side effects: Nausea, vomiting, diarrhea, decreased appetite, constipation, indigestion, abdominal pain, and injection site reactions (redness, itching, or mild swelling).
• Less common side effects: Headache, dizziness, fatigue, belching, gastroesophageal reflux, flatulence, and mild dehydration related to GI symptoms.
• Serious side effects (seek immediate medical attention): Signs of pancreatitis (persistent, severe abdominal pain that may radiate to the back, with or without vomiting), signs of gallbladder disease (severe abdominal pain, jaundice, fever), severe allergic reactions (rash, itching, swelling of face/lips/tongue, difficulty breathing), or symptoms of severe hypoglycemia (confusion, sweating, tremor, palpitations, blurred vision, loss of consciousness).
• This is not a complete list of side effects. Always read the package leaflet and consult your healthcare provider if you experience any unusual or persistent symptoms.

Storage Instructions:

Store in a refrigerator at 2–8°c, protected from light. Do not freeze. If the pen has been frozen, do not use it. After first use, storage conditions and in-use shelf life should follow the official leaflet; some pens may be kept at room temperature (up to a specified maximum) for a limited period – check the pack instructions. Keep the pen with the cap on when not in use. Store in a cool, dry place away from direct sunlight and heat sources. Keep container tightly closed and out of reach of children. Do not use after the expiry date printed on the pack.

Specifications:

• Product type: Prescription medicine for diabetes care and weight management.
• Active ingredient: Tirzepatide 5 mg per dose.
• Form: Solution for injection in a pre-filled Kwikpen.
• Strength: 5 mg/0.5 ml (reference concentration).
• Volume per pen: 2.4 ml solution.
• Doses per pen: 4 once-weekly doses.
• Route of administration: Subcutaneous injection (s.c.).
• Intended users: Adults with type 2 diabetes and/or adults with obesity or overweight with weight-related comorbidities, as prescribed by a physician.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.